Abbott Q1 sales rise 7.8% to $11.2 billion; GAAP EPS falls to $0.61
Abbott reported first-quarter 2026 sales of $11.164 billion, up 7.8% reported and 3.7% on a comparable basis, and GAAP diluted EPS of $0.61 versus $0.76 a year earlier. The company completed its Exact Sciences acquisition on March 23, 2026, and set 2026 adjusted diluted EPS guidance of $5.38 to $5.58, including $0.20 of acquisition dilution, which shareholders will weigh against the lower GAAP earnings.
Key points
- Q1 2026 GAAP net earnings were $1,077 million, down 18.7% from $1,325 million, while adjusted diluted EPS rose 5.5% to $1.15.
- Specified items reduced Q1 2026 GAAP earnings by $945 million after tax, or $0.54 per share, including $422 million of intangible amortization.
- Full-year 2026 comparable sales growth is projected at 6.5% to 7.5%, and second-quarter 2026 adjusted diluted EPS is projected at $1.25 to $1.31.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 16, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.